MTD vs. TEVA: Mettler-Toledo vs. Teva Pharmaceutical Stock Comparison

Company Profile

Mettler-Toledo (MTD) and Teva Pharmaceutical (TEVA) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but MTD is classified in Life Sciences Tools & Services while TEVA is classified in Pharmaceuticals.

Mettler-Toledo (MTD) trades as ordinary local shares, while Teva Pharmaceutical (TEVA) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Capital efficiency shows on one side only: Teva Pharmaceutical (TEVA) earns 6.65% on shareholders’ equity, ranked against its industry; Mettler-Toledo (MTD) has no ROE this period.

Mettler-Toledo (MTD) at 22.25% converts revenue to bottom-line profit above its industry’s benchmark range, while Teva Pharmaceutical (TEVA) at 2.94% keeps roughly the typical share for its industry.

Both Mettler-Toledo (MTD) at 28.70% and Teva Pharmaceutical (TEVA) at 27.40% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Mettler-Toledo (MTD) at 3.98% and Teva Pharmaceutical (TEVA) at 4.31% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: Mettler-Toledo (MTD) reports EPS growth of 3.88%, ranked against its industry; Teva Pharmaceutical (TEVA) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both Mettler-Toledo (MTD) at 1.10 and Teva Pharmaceutical (TEVA) at 0.95 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Debt sits unusually high against shareholders’ equity for both Mettler-Toledo (MTD) at 26.06 and Teva Pharmaceutical (TEVA) at 2.13 — each debt-to-equity ratio is above its industry benchmark range.

Financial Strength Metrics

Dividends

Neither Mettler-Toledo (MTD) nor Teva Pharmaceutical (TEVA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Mettler-Toledo (MTD) nor Teva Pharmaceutical (TEVA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Mettler-Toledo (MTD) at 37.38 is near its industry’s usual P/E ratio, while Teva Pharmaceutical (TEVA) at 99.09 sits above its peer range — an unusually expensive price for TEVA’s trailing earnings.

Teva Pharmaceutical (TEVA) at 2.89 sits in the cheaper P/S ratio quartile while Mettler-Toledo (MTD) at 8.16 prices around its industry’s middle — TEVA costs less per dollar of sales, though read it alongside growth and margins.

Teva Pharmaceutical (TEVA) at 6.23 sits near its industry’s typical P/B ratio, while Mettler-Toledo (MTD) at 442.71 prices above its benchmark range — MTD looks rich relative to book.

Valuation Metrics